Skip to main content
AstraZenecaIn development

SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus

Source: Autobound Signal API · 84 signals tracked for AstraZeneca · updated

Get AstraZeneca's live signals in Claude or ChatGPT, or by API

AskWhat changed at AstraZeneca this week? Use Autobound signals for astrazeneca.com.

What happened

AstraZeneca is developing cancer vaccines internally alongside its investments in cell therapies.

Source

Article excerpt

Sellas Life Sciences (SLS), ImmunityBio (IBRX) and Iovance Biotherapeutics (IOVA) ended October lower, while earnings updates from Merck (MRK) and AstraZeneca (AZN) put cancer vaccines, emerging competition and retail buyout hopes in focus. IOVA plunged 43% in October, while SLS shed 21% and IBRX fell 12%, all sharply underperforming the SPDR S&P Biotech ETF (XBI), which slipped 1.1%. Merck And AstraZeneca Map Their Cancer Push Merck’s earnings call offered cancer-vaccine optimism alongside signs of growing competition in lung and bladder cancer. While discussing its Moderna-partnered melanoma vaccine, research chief Dean Li said: “These results, building on the body of evidence from the phase IIb study, strengthen our confidence in the curative potential of intismeran when given in combination with KEYTRUDA.” Merck also highlighted a Keytruda-ADC combination that improved progression-free survival over Keytruda plus chemotherapy in a first-line lung-cancer study, and Phase 2 vaccine trials in bladder cancer. These programs point to potential future competition in markets targeted by Iovance and ImmunityBio. On AstraZeneca’s call, CEO Pascal Soriot highlighted its Summit Therapeutics partnership combining antibody-drug conjugates, or ADCs, with Ivonescimab. “We believe ADCs will become the backbone of treatment across tumor types, and this partnership gives flexibility to...

Keep reading with a free account

The rest of this article, and every signal for AstraZeneca, is in your free account.

Extracted from this sentence

AstraZeneca is also investing in cell therapies and developing cancer vaccines internally.

Extracted by Autobound

From the Signal API record
Event
In development

What this signalsWork in development often leads to new buying for tools, data and services.

Product
cancer vaccines

The full record

From the Signal API record

Topics and mentions

Product tags

  • medical

Extraction

Confidence
85%
Detected
Nov 2, 2026
signal_type
news
signal_subtype
is_developing

Use this data

Get every in development signal for AstraZeneca and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at AstraZeneca this week?”

  2. Send it to your own tools

    The Signal API returns in development signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/41db8ef4-60fa-26a3-51a3-6f01cf61c4cc returns this record as JSON. POST /v1/companies/enrich returns every signal for astrazeneca.com.

{
  "signal_id": "41db8ef4-60fa-26a3-51a3-6f01cf61c4cc",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-11-02T06:11:00+00:00",
  "company": {
    "name": "AstraZeneca",
    "domain": "astrazeneca.com"
  },
  "data": {
    "url": "https://www.tradingview.com/news/stocktwits:6407b84ae094b:0-sls-ibrx-iova-end-october-in-red-merck-and-astrazeneca-earnings-put-cancer-bets-and-buyout-hopes-in-focus/",
    "title": "SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus - TradingView",
    "excerpt": "Sellas Life Sciences (SLS), ImmunityBio (IBRX) and Iovance Biotherapeutics (IOVA) ended October lower, while earnings updates from Merck (MRK) and AstraZeneca (AZN) put cancer vaccines, emerging competition and retail buyout hopes in focus. IOVA plunged 43% in October, while SLS shed 21% and IBRX fell 12%, all sharply underperforming the SPDR S&P Biotech ETF (XBI), which slipped 1.1%. Merck And AstraZeneca Map Their Cancer Push Merck’s earnings call offered cancer-vaccine optimism alongside signs of growing competition in lung and bladder cancer. While discussing its Moderna-partnered melanoma vaccine, research chief Dean Li said: “These results, building on the body of evidence from the phase IIb study, strengthen our confidence in the curative potential of intismeran when given in combination with KEYTRUDA.” Merck also highlighted a Keytruda-ADC combination that improved progression-free survival over Keytruda plus chemotherapy in a first-line lung-cancer study, and Phase 2 vaccine trials in bladder cancer. These programs point to potential future competition in markets targeted by Iovance and ImmunityBio. On AstraZeneca’s call, CEO Pascal Soriot highlighted its Summit Therapeutics partnership combining antibody-drug conjugates, or ADCs, with Ivonescimab. “We believe ADCs will become the backbone of treatment across tumor types, and this partnership gives flexibility to...",
    "product": "cancer vaccines",
    "summary": "AstraZeneca is developing cancer vaccines internally alongside its investments in cell therapies.",
    "planning": false,
    "image_url": "https://s.tradingview.com/static/images/illustrations/news-story.jpg",
    "confidence": 0.85,
    "product_data": {
      "name": "cancer vaccines",
      "full_text": "cancer vaccines",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-11-02T06:11:00Z",
    "article_sentence": "AstraZeneca is also investing in cell therapies and developing cancer vaccines internally."
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.